Humira biosimilars set the stage for long-awaited 2023 US launches
Pharmaceutical Technology
DECEMBER 4, 2022
Humira is indicated for 10 adult and pediatric conditions, including Crohn’s disease, rheumatoid arthritis, and ulcerative colitis, as per its label. Others are made by big pharma giants like Boehringer Ingelheim , Novartis , or Pfizer , which has raised the expectations for a competitive market. .
Let's personalize your content